http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020165989-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2f7585ea1dfafdc5578f6155ae63d70b |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74 |
| filingDate | 2020-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d450ecdadba564e24cdda11df6e9fbe |
| publicationDate | 2020-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2020165989-A |
| titleOfInvention | Biomarker for diagnosis of risk of developing mental illness |
| abstract | PROBLEM TO BE SOLVED: To provide a biomarker for diagnosing a mental illness onset risk state (ARMS). SOLUTION: We have found that biopyrin and cortisol are significantly increased and immunoglobulin free κ chains (κFLC) and immunoglobulin free λ chains (λFLC) are significantly decreased in ARMS patients. Accordingly, the present invention provides an ARMS diagnostic biomarker comprising one or more selected from the group consisting of biopyrin, cortisol, κFLC or fragments thereof, and λFLC or fragments thereof. By measuring the amount of the biomarker for ARMS diagnosis of the present invention in a biological sample, AR can be performed quickly, easily and accurately. MS can be diagnosed. [Selection diagram] Fig. 1 |
| priorityDate | 2020-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 38.